Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The adipokine FABP4 is a key regulator of neonatal glucose homeostasis
Idit Ron, Reut Kassif Lerner, Moran Rathaus, Rinat Livne, Sophie Ron, Ehud Barhod, Rina Hemi, Amit Tirosh, Tzipora Strauss, Keren Ofir, Ido Goldstein, Itai M. Pessach, Amir Tirosh
Idit Ron, Reut Kassif Lerner, Moran Rathaus, Rinat Livne, Sophie Ron, Ehud Barhod, Rina Hemi, Amit Tirosh, Tzipora Strauss, Keren Ofir, Ido Goldstein, Itai M. Pessach, Amir Tirosh
View: Text | PDF
Research Article Endocrinology Metabolism

The adipokine FABP4 is a key regulator of neonatal glucose homeostasis

  • Text
  • PDF
Abstract

During pregnancy, fetal glucose production is suppressed, with rapid activation immediately postpartum. Fatty acid–binding protein 4 (FABP4) was recently demonstrated as a regulator of hepatic glucose production and systemic metabolism in animal models. Here, we studied the role of FABP4 in regulating neonatal glucose hemostasis. Serum samples were collected from pregnant women with normoglycemia or gestational diabetes at term, from the umbilical circulation, and from the newborns within 6 hours of life. The level of FABP4 was higher in the fetal versus maternal circulation, with a further rise in neonates after birth of approximately 3-fold. Neonatal FABP4 inversely correlated with blood glucose, with an approximately 10-fold increase of FABP4 in hypoglycemic neonates. When studied in mice, blood glucose of 12-hour-old WT, Fabp4–/+, and Fabp4–/– littermate mice was 59 ± 13 mg/dL, 50 ± 11 mg/dL, and 43 ± 11 mg/dL, respectively. Similar to our observations in humans, FABP4 levels in WT mouse neonates were approximately 8-fold higher compared with those in adult mice. RNA sequencing of the neonatal liver suggested altered expression of multiple glucagon-regulated pathways in Fabp4–/– mice. Indeed, Fabp4–/– liver glycogen was inappropriately intact, despite a marked hypoglycemia, with rapid restoration of normoglycemia upon injection of recombinant FABP4. Our data suggest an important biological role for the adipokine FABP4 in the orchestrated regulation of postnatal glucose metabolism.

Authors

Idit Ron, Reut Kassif Lerner, Moran Rathaus, Rinat Livne, Sophie Ron, Ehud Barhod, Rina Hemi, Amit Tirosh, Tzipora Strauss, Keren Ofir, Ido Goldstein, Itai M. Pessach, Amir Tirosh

×

Figure 6

Glycogen content of Fabp4WT and Fabp4–/– mouse neonates and recombinant FABP4 effect on blood glucose.

Options: View larger image (or click on image) Download as PowerPoint
Glycogen content of Fabp4WT and Fabp4–/– mouse neonates and recombinant ...
Fabp4WT and Fabp4–/– liver and muscle (left thigh) tissues were harvested and snap frozen at liquid nitrogen. (A and B) Glycogen content was determined in Fabp4WT (n = 19) and Fabp4–/– (n = 18) mouse neonatal liver (A) and Fabp4WT (n = 5) and Fabp4–/– (n = 5) mouse neonatal muscle (B) tissues using the Glycogen Assay Kit. (C) The ratio between blood glucose and liver glycogen content in each subject was compared between Fabp4WT (n = 14) and Fabp4–/– (n = 14) neonates. Recombinant FABP4 or saline was injected in Fabp4–/– mice (n = 7 for FABP4 and 8 for saline injected) within 12 hours from delivery. (D) Blood glucose was measured from mouse tail vein at 0, 15, and 30 minutes following injections. Statistical analysis was performed by Student’s t test. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts